



EXTACEF-100 DT/ EXTACEF-200 Tablets

Issue XI, No.31, 2025

Clinical Effectiveness and Safety of Cefixime in Managing Typhoid Fever in Indian Population: A Real-world Evidence Study

Parikh K et.al; Annals of Medicine and Medical Sciences; Vol.4; 2025

- The purpose of this study was to evaluate the effectiveness and safety of cefixime for managing typhoid fever among Indian patients.
- Multicenter, single-arm retrospective study assessed the data of 6247 patients from the medical records, who had received cefixime for typhoid during the period Jan 2023 to Apr 2024. At end-of-therapy (7 ± 2 days) and follow-up period (14 ± 2 days), assessment included clinical outcome, persisting symptoms, laboratory tests, and adverse event incidences.
- A majority of patients demonstrated clinical cure (96.68%) at 7 ± 2 days, which increased to 99.35% at 14 ± 2 days. Incidence of adverse events was rare, with 6 (0.09%) and 4 (0.06%) documented cases at 7 ± 2 days and 14 ± 2 days, respectively. The average duration of cefixime therapy was 8.21 (3.68) days, with a mean duration of hospital stay of 7.60 (3.84) days.
- Cefixime demonstrated high effectiveness in improving signs and symptoms of typhoid fever, with over 99% of the patients showing clinical cure at the post-therapy follow-up assessment.

Cefixime demonstrated high effectiveness and a favorable safety profile among Indian patients with typhoid fever.

